Market Overview

Hearing BTIG Desk Has Highlighted Zika Not Listed On INTERCEPT's FDA Label, Prevents Co From Making Zika Reduction Claims To Blood Centers/Hospitals

Share:

Latest Ratings for CERS

DateFirmActionFromTo
Apr 2016BTIG ResearchMaintainsBuy
Dec 2015WedbushDowngradesOutperformNeutral
Apr 2015BTIG ResearchInitiates Coverage onBuy

View More Analyst Ratings for CERS
View the Latest Analyst Ratings

Posted-In: Analyst Color News Rumors Price Target Reiteration Analyst Ratings

 

Related Articles (CERS)